


Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation

Supplementary Material



Supplementary Figure 1: NALM-6, SEM, TOM-1 and SUP-B15 cell lines were treated with Torin-2 or RAD001, either alone or in combination with MK-2206 for 48h. Results are the mean of three different experiments \pm SD. Combination index (CI) value for each data point was calculated with the appropriate software for dose effect analysis (Calculusyn).